Pfizer and Roche both used ADA26 to push incremental dose-and-combination narratives for their obesity programs. Pfizer presented additional data supporting monthly dosing of berobenatide (formerly PF-08653944), including outcomes after transitioning from weekly injections and continuing weight loss out to 28 weeks. Separately, Roche outlined plans for a Phase 2 trial combining petrelintide and enicepatide. The company framed the pairing as a way to potentially combine best-in-class safety and efficacy characteristics. Together, the updates highlight how obesity drug developers are now competing not only on endpoints like weight-loss magnitude, but also on dosing convenience, durability of effect, and combination strategy designed to differentiate from weekly injectables already in mid- and late-stage development.